Figure 1.
A) Schematic representation of the mechanism by which biomimetic mini DC nanovaccine for enhanced adaptive T cell–based immunotherapy for ovarian cancer. B) Comparison between mini DC and conventional DC cells.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.